Kenneth H. Shumak, MD; Gail A. Rock, PhD, MD; Rama C. Nair, PhD; The Canadian Apheresis Group.
To determine the incidence and timing of relapses in patients who have recovered from an acute episode of thrombotic thrombocytopenic purpura.
Clinical follow-up for 3 to 10 years.
General community outpatient study; patients who had relapse were hospitalized.
63 of 72 surviving patients who had participated in a randomized study that compared plasma exchange and plasma infusion as treatments for thrombotic thrombocytopenic purpura and for whom continued clinical follow-up was obtained.
Recurrence of thrombotic thrombocytopenic purpura as defined by a decrease in platelet count to less than 100 × 109/L and by the onset of microangiopathic hemolytic anemia as identified by erythrocyte fragmentation in a peripheral blood film.
37 of the 63 patients have not had recurrence of thrombotic thrombocytopenic purpura and have remained completely well; 6 patients have not had recurrence but have developed other medical problems; 3 patients have not had recurrence but have residual neurologic defects from the original episode; and 17 patients have had one or more recurrences, occurring 7 months to 8 years after the original episode. As determined by Kaplan-Meier analysis, the projected recurrence rate after 10 years in all surviving patients is 36% (95% CI, 23% to 59%).
More than one third of patients who survive an acute episode of thrombotic thrombocytopenic purpura will have at least one relapse during the following 10 years.
Shumak KH, Rock GA, Nair RC, . Late Relapses in Patients Successfully Treated for Thrombotic Thrombocytopenic Purpura. Ann Intern Med. 1995;122:569–572. doi: 10.7326/0003-4819-122-8-199504150-00002
Download citation file:
Published: Ann Intern Med. 1995;122(8):569-572.
Coagulopathies, Hematology/Oncology, Platelet Disorders.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use